Malaria

Drug resistance and containment

Drug resistance and containment
Sarah Hoibak/MENTOR

Efficacious antimalarial medicines are critical to malaria control, and continuous monitoring of their efficacy is needed to inform treatment policies in malaria-endemic countries, and to ensure early detection of, and response to, drug resistance. The emergence of P. falciparum resistance to artemisinin is an urgent public health concern, threatening the sustainability of the ongoing global effort to reduce the burden of malaria. In January 2011, WHO released the Global Plan for Artemisinin Resistance Containment (GPARC), calling on countries and global malaria partners to implement a five-pillar strategy to prevent and contain artemisinin resistance.


Antimalarial drug efficacy

Efficacious antimalarials are critical to malaria control, and continuous efficacy monitoring is needed to inform treatment policies and to ensure early detection of drug resistance.

Antimalarial drug resistance

To date, parasite resistance has been documented in three of the five malaria species known to affect humans: P. falciparum, P. vivax and P. malariae.

Containment of artemisinin resistance

Containment activities are ongoing in all affected countries in the Greater Mekong Subregion. Urgent action is required to prevent the situation from worsening.

WHO updates on artemisinin resistance

The WHO Global Malaria Programme issues regular updates about the status of artemisinin resistance in affected countries.

Emergency response to artemisinin resistance in the Greater Mekong subregion

The regional hub coordinates interventions and containment efforts in Cambodia, the Lao People’s Democratic Republic, Myanmar, Thailand and Viet Nam.

Key documents

Contact us

Global Malaria Programme
World Health Organization
20 Avenue Appia
1211 Geneva 27
Switzerland
Tel: +41 22 791 2533
Fax: +41 22 791 4824
E-mail: infogmp@who.int